Form 4: BioLife Solutions CTO Sells Shares for Tax Obligations

BioLife Solutions' Chief Technology Officer, Sean Werner, sold 275 shares of common stock at $27.82 per share to cover tax withholding obligations.

Summary

• Sean Werner, Chief Technology Officer of BioLife Solutions Inc. (BLFS), reported the sale of 275 shares of common stock.
• The transaction occurred on October 20, 2025, with shares sold at a price of $27.82 each.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted by Mr. Werner effective July 17, 2024.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock.
• Following this transaction, Mr. Werner directly beneficially owns 26,037 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider sale for tax withholding purposes, which is a common occurrence and does not indicate a change in company fundamentals or management's outlook.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, demonstrating adherence to SEC regulations regarding insider trading and providing transparency.

Negatives

• An insider sale, even for tax purposes, could be misinterpreted by some investors as a lack of confidence, though the context of tax withholding mitigates this concern.

Risks

• No specific operational or financial risks to BioLife Solutions Inc. were disclosed in this Form 4 filing. The primary 'risk' is the potential for misinterpretation of the insider sale by the market.

Future Outlook

NA

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of 07-17-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

This filing reports a routine insider transaction, specifically a sale of shares by a company officer to cover tax obligations. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing reports a routine, pre-planned sale of shares by the Chief Technology Officer to cover tax withholding obligations related to restricted stock vesting. This is a common occurrence and does not indicate a change in the company's fundamentals or management's long-term outlook, thus a 'hold' recommendation is appropriate as no new material information affecting valuation or future prospects is presented.

Keywords

BioLife Solutions, BLFS, Sean Werner, Insider Trading, Form 4, Stock Sale, Chief Technology Officer, Tax Withholding, 10b5-1 Plan